

0110



IN THE UNITED STATES PATENT OFFICE

NOV - 3 1997

In re: Klimko et al.

Serial Number: 08/917,795

Filed: August 21, 1997

Examiner: NYA

Group Art Unit: NYA

For: USE OF CLOPROSTENOL
AND FLUPROSTENOL
ANALOGUES TO TREAT
GLAUCOMA AND OCULAR
HYPERTENSION

**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER 37 CFR §1.97(b)(3)**

Assistant Commissioner for Patents
Box DD
Washington, DC 20231

Sir:

Pursuant to the duty of disclosure under 37 CFR §§1.56, 1.97(b) and 1.98, Applicants submit the attached PTO Form 1449 and one (1) copy of a reference. This disclosure statement is being submitted within three (3) months of the filing date of the application.

Applicants request that the references listed in the accompanying PTO Form 1449 be considered during prosecution of the above-referenced application, and that these references appear among the "References Cited" on any patent issuing herefrom.

Respectfully submitted,

ALCON LABORATORIES, INC.

Date: 10-29-97

By: 
Barry L. Copeland
Reg. No. 34,801

ADDRESS FOR CORRESPONDENCE:
Barry L. Copeland
Patent Department Q-148
Alcon Laboratories, Inc.
6201 South Freeway
Fort Worth, Texas 76134-2099
(817) 551-4322

Atty. Docket No. 1407B